RxDoctor Payments Data

Julie Anderson, MD

Family Medicine · Saint Cloud, MNNPI 1801825278

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,114 of the $2,765 with a category attached, or 76.4%. E.r. Squibb & Sons, L.L.C. accounts for 77.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $2,132 and has fallen 89.5% since, to $224 in 2025. Among family medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,765in general payments, 2019–2025

Across 41 payments — averaging $67.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Astellas Pharma US Inc$128
  • GSK$50
  • Phadia US Inc.$49
  • Sanofi Pasteur Inc.$39
  • AbbVie$38
  • plus $314 from 19 others

What the payments were for

  • Consulting fees$2,11476%
  • Food & beverage$63623%
  • Education$151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,765 in reported general payments places this provider in the 95th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$141,125
Medicare patients
284
Services billed
3,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$144,241
EliquisApixaban83$103,700
TrulicityDulaglutide51$85,270
XareltoRivaroxaban24$36,193
MounjaroTirzepatide29$34,181
JardianceEmpagliflozin25$31,642
AbrysvoRsv Vacc, Pref A And Pref B/Pf71$23,598
Budesonide ErBudesonide13$11,757
ShingrixVaricella-Zoster Ge/As01b/Pf43$9,784
Breo ElliptaFluticasone/Vilanterol14$6,209
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,967
Ventolin HfaAlbuterol Sulfate64$5,407
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf72$5,249
Omeprazole336$5,247
Atorvastatin Calcium343$5,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$144,241108 claims
Lilly USA, LLCTrulicity, Mounjaro$11$119,45180 claims
Boehringer IngelheimJardiance$15$31,64225 claims
GSKShingrix, Breo Ellipta$50$15,99257 claims
AbbVieSynthroid$38$2,67038 claims
MerckAsmanex$12$1,98413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Saint Cloud

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →